Peripheral vascular disease is associated with OP and hip fractures. #ACR18 @RheumNow Abstract 2305. pic.twitter.com/VhFz3KzLNY
— William Shergy (@WilliamShergy) October 23, 2018
2323 survival after hip fragility fract in OP: ⬇️ survival in pts >=80 yo,partially & totally dependent pts& pts w/ ⬆️ serum beta-crosslaps (HR 4.27, p=0.007). Higher femur BMD& T-score predict better survival. Gender, surgery, vit D& ostecalcin had no effect. #acr18 @rheumnow
— Olga Petryna (@DrPetryna) October 23, 2018
How to deal with the complications of OP therapy. #ACR18 @RheumNow Abstract 4M092 pic.twitter.com/ZvzbBNR162
— William Shergy (@WilliamShergy) October 22, 2018
#ACR18 Plenary II:
#1818 Dr Saag – denosumab vs risedronate in GC-treated patients, 24 month data. Denosumab clearly better for BMD improvement. But beware surrogate outcome measures (no diff in fractures, but not powered for this). No diff in AEs (inc infection). @RheumNow pic.twitter.com/PpfSYzthey— ǝlʇʇıɥʍ ɯɐs (@samwhittle) October 22, 2018
Plenary session by Ken Saag on GIOP 24 mth data alendronate vs denosumab. Greater improvement in BMD at 24 mths (DmAb vs alendronate) for BMD improvement for lumbar spine,FN and total hip. Adverse event rates reassuring @RheumNow #ACR18 full video later today on this abstract pic.twitter.com/v3mC8ovc4B
— Dr. Arthur Lau (@ArthurRheum) October 22, 2018
Abst1818 24 mo randomized trial: Denosumab superior to risedronate in GC treated OP. Greater improvement of LS&HIP BMD at all timepoints assessed through 24 mo. AE, sAR & fractures similar between groups. #acr18 @rheumnow pic.twitter.com/DVMC8zdKkH
— Olga Petryna (@DrPetryna) October 22, 2018
#ACR18 Cosman on osteoporosis. Screen for spinal fractures as they go unnoticed. Importantly start therapy with anabolic then go to bisphosphonate. Very sensible and worth the cost.
— John Axford (@ProfAxford) October 21, 2018
This is the review course slide. pic.twitter.com/mtp2l31hsv
— Dr. Rachel Tate (@uptoTate) October 22, 2018
Osteoporosis: anabolic agents appear to have more rapid and greater effects compared to antoresorptive agents. @RheumNow #ACR18
— Brittany A (@MissbeeMD) October 20, 2018
Osteoporosis: BMD strong predictor of fracture risk in untreated patients @RheumNow #ACR18
— Brittany A (@MissbeeMD) October 20, 2018
Osteoporosis: treatment sequence matters in very low BMD. Anabolics provide greater BMD when used first, then follow with antiresorptive. @RheumNow #ACR18
— Brittany A (@MissbeeMD) October 20, 2018
Ever wondered what to do if your pt on bisphosphonates fractured? @RheumNow #ACR18 pic.twitter.com/i5c7CjL09d
— k dao (@KDAO2011) October 20, 2018
Don’t miss treating these high risk Osteoporosis patients. #ACR18 @RheumKnow Review Course pic.twitter.com/T4p0o6eMI0
— William Shergy (@WilliamShergy) October 21, 2018
Is it time to change our sequence of therapy in treating Osteoporosis? #ACR18 RheumNow Review Course pic.twitter.com/uYaRs7fd7P
— William Shergy (@WilliamShergy) October 21, 2018
Teriparatide reduced vertebral fractures by 90% compared to Alendronate over 18 months in glucocorticoid induced osteoporosis. @RheumNow #ACR18
— Dr. Rachel Tate (@uptoTate) October 21, 2018
Abst883 seropositivity associated w/increased risk of osteoporosis in male RA pts<70yo. Out of 67 osteoporosis patients
RF+ vs RF- 30 and 9 respectively, chi- square 0.0076.
CCP+ vs CCP- 18 and 7, chi- square 0.027. #acr18 @rheumnow— Olga Petryna (@DrPetryna) October 21, 2018